​​Normally new technologies are overrated in short term but underrated in long term. The best example to proof this saying is artificial intelligence. There is hardly any health challenge that will not be cured by the application of big data, machine learning and artificial intelligence. But, whoever investigates the real word hardly finds any existing solutions going beyond the use of «simple» algorithms. Actually this is not a bad thing as crucial questions still remain without an answer - or even unquestioned – which clearly show how much underrated artificial intelligence actually is. Can we really regulate machines that learn by themselves? And, how can we prevent that the platforms that provide for us artificial intelligences will not misuse their power?

DayOne: Introduction and panel discussion with speakers and guests 

Moderation: Thomas Brenzikofer, BaselArea.swiss, Director DayOne Initiative 

Networking Apéro

R iche

Sponsored by

BaselArea.swiss DayOne

Panel Session

DayOne Experts: Artificial Intelligence

"the holy grail to healthcare innovation?"

organized by DayOne - an iniative managed by BaselArea.swiss 

Key Note Presentation (Download

Prof. Dr. Susan Gasser

Director Friedrich Miescher Institute (FMI), Basel

Susan M. Gasser is the director of the Friedrich Miescher Institute for Biomedical Research, a position she assumed in 2004. In parallel, she holds a professorship at the University of Basel and runs an active research laboratory at the FMI. Prior to joining the FMI, she was a professor in the Department of Molecular Biology at the University of Geneva.

Susan studied at the University of Chicago and completed her PhD at the University of Basel (Biochemistry; G. Schatz), working on the import of mitochondrial proteins. As a postdoctoral fellow, she studied the long-range folding of the genome in flies and human cells. She identified topoisomerase II as a structural component of mitotic chromosomes, and AT-rich sequences as elements of loop organization. From 1986-2001, as a research group leader at the Swiss Institute for Experimental Cancer Research, she combined genetic approaches and fluorescence microscopy to examine the impact of nuclear organization on genome function – specifically on heritable gene repression in yeast.

Susan Gasser's studies have continued to examine how nuclear organization impinges on mechanisms of repair and replication fork stability and on epigenetic inheritance of cell fate decisions. She exploits the genetics of model organisms in her studies, as well as quantitative live fluorescence imaging. Her laboratory identified mechanisms that tether telomeres and silent chromatin at the nuclear envelope. In parallel, they identified roles for RecQ helicases, checkpoint kinases and ORC in the maintenance of genome integrity. Over the last 10 years she has examined the role of nuclear organization and heterochromatin in the development of the nematode, C. elegans. The laboratory has contributed to our understanding of signals and anchors involved in chromatin positioning, both for active and inactive genes, and for various types of DNA double strand break repair.

She has authored more than 250 primary articles and reviews, and has received a number of awards for her work, including election to the Académie de France, to the Swiss Academy of Medical Sciences, FEBS | EMBO Women in Science Award 2012, the Weizmann Institute Women in Science award 2013, the INSERM International Prize in 2011, and both the Otto Naegeli Award and the Gregor Mendel Medal in 2006. She was a member of the President’s Science and Technology Advisory Council of the European Commission, and serves on scientific review panels for institutes across Europe.



Artificial Intelligence in Life Sciences

Will Artificial Intelligence

be little more than

the latest science fiction trend

soon to fade away?

Or will it disrupt

the way we define

and deliver health care? 

Find out more at the next Life Science Forum Basel conference

jointly created as a DayOne Expert Event...​

From Data to Value 

Demonstrating real-world value of medicines using predictive analytics and machine learning

Dr. Tim Wintermantel 

Senior Principal, Real World Insights at IQVIA


AI has a Lot to Offer to Pharma

From finding new drugs to better physician engagement

Simon Tilley

Life Science Director Northern Europe, SAS UK

Healthier Lifestyles – Triggered by AI

How Big Data and AI help insurers to motivate their members to adopt healthier Lifestyles

Manuel Heuer, COO

dacadoo AG

Re-Imagining Clinical Trials with Digital Biomarkers

How apps and wearables could be used in clinical Trials

Dr. Czuee Morey

Business Analyst for Clinical Development, Wega Informatik AG, Basel

AI and Analytics in Clinical Research with Synthetic Controls

Learn how different AI applications can help you to better manage the operational health of clinical trials

Sean McDonell

Principal, Data and Analytics at Medidata Solutions

Challenges and Opportunities  in Digital Transformation

How to compete in the data driven digital transformation in the pharmaceutical industry

Peter Lange

Senior Business Consultant Life Sciences, NNIT